Effect of acacia polyphenol on glucose homeostasis in subjects with impaired glucose tolerance: A randomized multicenter feeding trial

Experimental and Therapeutic Medicine

Volumn 5, Issue 6, 2013, Pages 1566-1572

  Ogawa, Sosuke ^a   Matsumae, Tomoyuki ^a   Kataoka, Takeshi ^a   Yazaki, Yoshikazu ^b   Yamaguchi, Hideyo ^c  

^a Mimozax Co Ltd   (Japan)

^b MONASH UNIVERSITY   (Australia)

^c TOTAL   (France)

Author keywords

Acacia polyphenol; Dietary supplement; Glucose homeostasis; Impaired glucose tolerance; Insulin; Oral glucose tolerance test

Indexed keywords

ACACIA POLYPHENOL; FLAVONOID; HEMOGLOBIN A1C; PLACEBO; PLANT MEDICINAL PRODUCT; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ACACIA MEARNSII; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEMATOLOGY; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

EID: 84876583868     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.1029     Document Type: Article

References (31)

1. Wild S, Roglic G, Green A, Sicree R and King H: Global prevalence of diabetes: estimates for the year 2000 and projection for 2030. Diabetes Care 27: 1047-1053, 2004.
2. Danaei G, Finucane MM, Lu Y, et al: National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 378: 31-40, 2011.
3. International Diabetes Federation: Diabetes Atlas. 3rd edition. International Diabetes Federation, Brussels, Belgium, 2006.
4. Chen JCN, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoo KH and Hu FB: Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 301: 2129-2140, 2009.
5. Tuomilehto J, Lindström J, Eriksson JG, et al: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343-1350, 2001.
6. Lindström J, Ilanne-Parikka P, Peltonen M, et al: Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: Follow-up of the Finish Diabetes Prevention Study. Lancet 368: 1673-1679, 2006.
7. Hanhineva K, Törrönen R, Bondia-Pons I, Pekkinen J, Kolehmainen M, Mykkänen H and Poutanen K: Impact of dietary polyphenols on carbohydrate metabolism. Int J Mol Sci 11: 1365-1402, 2010.
8. Aron PM and Kennedy JA: Flavan-3-ols: nature, occurrence and biological activity. Mol Nutr Food Res 52: 79-104, 2008.
9. Yazaki Y: Acacia storyi: a potential tannin-producing species. Australian Forestry 60: 24-28, 1997.
10. Roux DG and Maihs EA: Condensed tannins. 3. Isolation and estimation of (-)-7:3':4':5'-tetrahydroxyflavan-3-ol, (+)-catechin and (+)-gallocatechin from black-wattle-bark extract. Biochem J 74: 44-49, 1960.
11. Roux DG and Paulus E: Condensed tannins. 7. Isolation of (-)-7:3':4'-trihydroxyflavan-3-ol [(-)-fisetinidol], a naturally occurring catechin from black-wattle heartwood. Biochem J 78: 120-123, 1961.
12. Roux DG, Maihs EA and Paulus E: Condensed tannins. 9. Distribution of flavonoid compounds in the heartwood and barks of some interrelated wattles. Biochem J 78: 834-839, 1961.
13. Kusano R, Ogawa S, Matsuo Y, Tanaka T, Yazaki Y and Kouno I: α-Amylase and lipase inhibitory activity and structural characterization of acacia bark proanthocyanidins. J Nat Prod 74: 119-128, 2011.
14. Drewes SE and Roux DG: Condensed tannins. 15. Interrelationships of flavonoid components in wattle-bark extract. Biochem J 87: 167-172, 1963.
15. Roux DG and Evelyn SR: Condensed tannins. 1. A study of complex leuco-anthocyanins present in condensed tannins. Biochem J 69: 530-538, 1958.
16. Zheng G, Lin Y and Yazaki Y: Comparing molecular size distribution of tannin extracts from Acacia mearnsii bark from different countries. Holzforschung 42: 407-408, 1988.
17. Ikarashi N, Toda T, Okaniwa T, Ito K, Ochiai W and Sugiyama K: Anti-obesity and anti-diabetic effects of acacia polyphenol in obese diabetic KKAy mice fed high-fat diet. Evid Based Complement Alternat Med 2011: 952031, 2011.
18. Ikarashi N, Takeda R, Ito K, Ochiai W and Sugiyama K: The inhibition of lipase and glucosidase activities by acacia polyphenol. Evid Based Complement Alternat Med 2011: 272075, 2011.
19. Kataoka T, Ogawa S, Matsumae T, Yazaki Y and Yamaguchi H: Safety of acacia polyphenol dietary supplement: safety evaluation studies in healthy male adults. Pharmacometrics 80: 43-52, 2011 (In Japanese).
20. Japan Diabetes Society: Guidelines for Treatment of Diabetes 2002-2003. Bunkodo, Tokyo, 2002 (In Japanese).
21. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 27 (Suppl 1): S5-S10, 2004.
22. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G and Quon MJ: Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85: 2402-2410, 2000.
23. Bonora E, Kiechl S, Willeit J, et al: Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 47: 1643-1649, 1998.
24. Grassi D, Lippi C, Necozione S, Desideri G and Ferri C: Short-term administration of dark chocolate is followed by a significant increase in insulin sensitivity and a decrease in blood pressure in healthy persons. Am J Clin Nutr 81: 611-614, 2005.
25. Grassi D, Desideri G, Necozione S, et al: Blood pressure is reduced and insulin sensitivity increased in glucose-intolerant, hypertensive subjects after 15 days of consuming high-polyphenol dark chocolate. J Nutr 138: 1671-1676, 2008.
26. The DECODE study group on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354: 617-662, 1999.
27. Osei K, Rhinesmith S, Gaillard T and Schuster D: Impaired insulin sensitivity, insulin secretion, and glucose effectiveness predict future development of impaired glucose tolerance and type 2 diabetes in prediabetic African Americans: implications for primary diabetes prevention. Diabetes Care 27: 1439-1446, 2004.
28. Thalhammer C, Balzuweit B, Busjahn A, Walter C, Luft FC and Haller H: Endothelial cell dysfunction and arterial wall hypertrophy are associated with disturbed carbohydrate metabolism in patients at high risk for cardiovascular disease. Arterioscler Thromb Vas Biol 19: 1173-1179, 1999.
29. McNeeley MJ, Boyko EJ, Leonetti DL, Kahn SE and Fujimoto WY: Comparison of a clinical model, the oral glucose tolerance test, and fasting glucose for prediction of type 2 diabetes risk in Japanese Americans. Diabetes Care 26: 758-763, 2003.
30. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C and Reaven G: Use of metabolic markers to identify overweight individuals who are insulin resistant. Am Intern Med 139: 802-809, 2003.
31. Kashiwabara H, Inaba M, Maruno Y, et al: Insulin levels during fasting and the glucose tolerance test and Homa's index predict subsequent development of hypertension. J Hypertens 18: 83-88, 2000.